|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Meeting Report |
Duke University Medical Center, Division of Neurosurgery, Durham, NC 27710
1 Address correspondence and reprint requests to John H. Sampson, MD, PhD, Duke University Medical Center, Division of Neurosurgery, Box 3807, 4505 Busse Bldg., Durham, NC 27710.
References
Alleva, D.G., Burger, C.J., and Elgert, K.D. (1994) Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2. J. Immunol. 153,1674 -1686.[Abstract]
Andreansky, S.S., He, B., Gillespie, G.Y., Soroceanu, L., Markert,
J., Chou, J., Roizman, B., and Whitley, R.J. (1996) The
application of genetically engineered herpes simplex viruses to the treatment
of experimental brain tumors. Proc. Natl. Acad. Sci. U. S.
A. 93,11313
-11318.
Andreansky, S., Soroceanu, L., Flotte, E.R., Chou, J., Markert,
J.M., Gillespie, G.Y., Roizman, B., and Whitley, R.J. (1997)
Evaluation of genetically engineered herpes simplex viruses as oncolytic
agents for human malignant brain tumors. Cancer Res.
57,1502
-1509.
Anichini, A., Mortarini, R., Maccalli, C., Squarcina, P., Fleischhauer, K., Mascheroni, L., and Parmiani, G. (1996) Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J. Immunol. 156,208 -217.[Abstract]
Arienti, F., Sule-Suso, J., Belli, F., Mascheroni, L., Rivoltini, L., Melani, C., Maio, M., Cascinelli, N., Colombo, M.P., and Parmiani, G. (1996) Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum. Gene Ther. 7,1955 -1963.[ISI][Medline]
Ashley, D.M., Faiola, B., Nair, S., Hale, L.P., Bigner, D.D., and
Gilboa, E. (1997) Bone marrow-generated dendritic cells pulsed
with tumor extracts or tumor RNA induce antitumor immunity against central
nervous system tumors. J. Exp. Med.
186,1177
-1182.
Batra, S.K., Castelino-Prabhu, S., Wikstrand, C.J., Zhu, X., Humphrey, P.A., Friedman, H.S., and Bigner, D.D. (1995) Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ. 6,1251 -1259.[Abstract]
Belli, F., Arienti, F., Sule-Suso, J., Clemente, C., Mascheroni, L., Cattelan, A., Sanatonio, C., Gallino, G.F., Melani, C., Rao, S., Colombo, M.P., Maio, M., Cascinelli, N., and Parmiani, G. (1997) Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability. Cancer Immunol. Immunother. 44,197 -203.[CrossRef][ISI][Medline]
Berger, T., Weerth, S., Kojima, K., Linington, C., Wekerle, H., and Lassmann, H. (1997) Experimental autoimmune encephalomyelitis: the antigen specificity of T lymphocytes determines the topography of lesions in the central and peripheral nervous system. Lab. Invest. 76,355 -364.[ISI][Medline]
Biernat, W., Kleihues, P., Yonekawa, Y., and Ohgaki, H. (1997a) Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J. Neuropathol. Exp. Neurol. 56,180 -185.[ISI][Medline]
Biernat, W., Tohma, Y., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (1997b) Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta. Neuropathol. (Berl) 94,303 -309.[CrossRef][Medline]
Bigner, D.D., Pitts, O.M., and Wikstrand, C.J. (1981) Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue. J. Neurosurg. 55,32 -42.[ISI][Medline]
Bloom, H.J., Peckham, M.J., Richardson, A.E., Alexander, P.A., and Payne, P.M. (1973) Glioblastoma multiforme: a controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy. Br. J. Cancer 27,253 -267.[ISI][Medline]
Bodmer, S., Strommer, K., Frei, K., Siepl, C., de Tribolet, N., Heid, I., and Fontana, A. (1989) Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J. Immunol. 143,3222 -3229.[Abstract]
Bohm, C.M., Mulder, M.C., Zennadi, R., Notter, M., Schmitt-Graff, A., Finn, O.J., Taylor-Papadimitriou, J., Stein, H., Clausen, H., Riecken, E.O., and Hanski, C. (1997) Carbohydrate recognition on MUC1-expressing targets enhances cytotoxicity of a T cell subpopulation. Scandinavian J. Immunol. 46, 27-34.[CrossRef][ISI][Medline]
Borrow, P., Cornell, J.L., Ruppe, M.D., and Mucke, L. (1995) Immunization-induced inflammatory infiltration of the central nervous system in transgenic mice expressing a microbial antigen in astrocytes. J. Neuroimmunol. 61,133 -149.[CrossRef][ISI][Medline]
Braun, D.P., Penn, R.D., Flannery, A.M., and Harris, J.E. (1982) Immunoregulatory cell function in peripheral blood leukocytes of patients with intracranial gliomas. Neurosurgery 10,203 -209.[ISI][Medline]
Brooks, W.H., Netsky, M.G., Normansell, D.E., and Horwitz, D.A. (1972) Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J. Exp. Med. 136,1631 -1647.[Abstract]
Brooks, W.H., Caldwell, H.D., and Mortara, R.H. (1974) Immune responses in patients with gliomas. Surg. Neurol. 2,419 -423.[ISI][Medline]
Brooks, W.H., Roszman, T.L., and Rogers, A.S. (1976) Impairment of rosette-forming T lymphoctyes in patients with primary intracranial tumors. Cancer 37,1869 -1873.[CrossRef][ISI][Medline]
Brooks, W.H., Roszman, T.L., Mahaley, M.S., and Woosley, R.E. (1977) Immunobiology of primary intracranial tumours. II. Analysis of lymphocyte subpopulations in patients with primary brain tumours. Clin. Exp. Immunol. 29,61 -66.[ISI][Medline]
Bullard, D.E., Thomas, D.G., Darling, J.L., Wikstrand, C.J., Diengdoh, J.V., Barnard, RO, Bodmer, J.G., and Bigner, D.D. (1985) A preliminary study utilizing viable HLA mismatched cultured glioma cells as adjuvant therapy for patients with malignant gliomas. Br. J. Cancer 51,283 -289.[ISI][Medline]
Burger, P.C., Heinz, E.R., Shibata, T., and Kleihues, P. (1988) Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J. Neurosurg. 68,698 -704.[ISI][Medline]
Chambers, R., Gillespie, G.Y., Soroceanu, L., Andreansky, S.,
Chatterjee, S., Chou, J., Roizman, B., and Whitley, R.J. (1995)
Comparison of genetically engineered herpes simplex viruses for the treatment
of brain tumors in a scid mouse model of human malignant glioma.
Proc. Natl. Acad. Sci. U. S. A.
92,1411
-1415.
Cheung, N.K., Cheung, I.Y., Canete, A., Yeh, S.J., Kushner, B.,
Bonilla, M.A., Heller, G., and Larson, S.M. (1994a) Antibody
response to murine anti-GD2 monoclonal antibodies: correlation with patient
survival. Cancer Res.
54,2228
-2233.
Cheung, N.K., Kushner, B.H., Yeh, S.J., and Larson, S.M. (1994b) 3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: A phase II study. Prog. Clin. Biol. Res. 385,319 -328.[Medline]
Chiocca, E.A. (1995) Brain tumor gene therapy in mice with a novel "suicide" gene: the cyclophosphamide-activating CYP2B1 gene. Clin. Neurosurg. 42,370 -382.[Medline]
de Martin, R., Haendler, B., Hofer-Warbinek, R., Gaugitsch, H., Wrann, M., Schlusener, H., Seifert, J.M., Bodmer, S., Fontana, A., and Hofer, E. (1987) Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. EMBO J. 6,3673 -3677.[ISI][Medline]
Elliott, L., Brooks, W., and Roszman, T. (1987) Role of interleukin-2 (IL-2) and IL-2 receptor expression in the proliferative defect observed in mitogen-stimulated lymphocytes from patients with gliomas. J. Natl. Cancer Inst. 78,919 -922.
Elliott, L.H., Brooks, W.H., and Roszman, T.L. (1987) Activation of immunoregulatory lymphocytes obtained from patients with malignant gliomas. J. Neurosurg. 67,231 -236.[ISI][Medline]
Elliott, L.H., Brooks, W.H., and Roszman, T.L. (1990) Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors. J. Clin. Invest. 86, 80-86.
Elliott, L.H., Brooks, W.H., and Roszman, T.L. (1992) Suppression of high affinity IL-2 receptors on mitogen activated lymphocytes by glioma-derived suppressor factor. J. Neurooncol. 14, 1-7.[Medline]
Fakhrai, H., Dorigo, O., Shawler, D.L., Lin, H., Mercola, D.,
Black, K.L., Royston, I and Sobol, R.E. (1996) Eradication of
established intracranial rat gliomas by transforming growth factor beta
antisense gene therapy. Proc. Natl. Acad. Sci. U. S.
A. 93,2909
-2914.
Finn, O.J., Jerome, K.R., Henderson, R.A., Pecher, G., Domenech, N., Magarian-Blander, J., and Barratt-Boyes, S.M. (1995) MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol. Rev. 145,61 -89.[CrossRef][ISI][Medline]
Fontana, A., Hengartner, H., de Tribolet, N., and Weber, E. (1984) Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J. Immunol. 132,1837 -1844.[Abstract]
Herlyn, D., Harris, D., Zaloudik, J., Sperlagh, M., Maruyama, H., Jacob, L., Kieny, M.P., Scheck, S., Somasundaram, R., Hart, E. (1994) Immunomodulatory activity of monoclonal anti-idiotypic antibody to anti-colorectal carcinoma antibody CO17-1A in animals and patients. J. Immunother. Emphasis Tumor Immunol. 15,303 -311.[Medline]
Herlyn, D., Somasundaram, R., Li, W., and Maruyama, H. (1996) Anti-idiotype cancer vaccines: past and future. Cancer Immunol. Immunother. 43, 65-76.[CrossRef][ISI][Medline]
Herrlinger, U., Kramm, C.M., Johnston, K.M., Louis, D.N., Finkelstein, D., Reznikoff, Dranoff, G., Breakefield, X.O., and Yu, J.S. (1997) Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther. 4, 345-352.[ISI][Medline]
Hishii, M., Nitta, T., Ishida, H., Ebato, M., Kurosu, A., Yagita, H., Sato, K., and Okumura, K. (1995) Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery 37,1160 -1167.[ISI][Medline]
Hoshimaru, M., Ray, J., Sah, D.W., and Gage, F.H.
(1996) Differentiation of the immortalized adult neuronal
progenitor cell line HC2S2 into neurons by regulatable suppression of the
v-myc oncogene. Proc. Natl. Acad. Sci. U. S. A.
93,1518
-1523.
Huang, H.S., Nagane, M., Klingbeil, C.K., Lin, H., Nishikawa, R.,
Ji, X.D., Huang, C.M., Gill, G.N., Wiley, H.S., and Cavenee, W.K.
(1997) The enhanced tumorigenic activity of a mutant epidermal
growth factor receptor common in human cancers is mediated by threshold levels
of constitutive tyrosine phosphorylation and unattenuated signaling.
J. Biol. Chem. 272,2927
-2935.
Huettner, C., Paulus, W., and Roggendorf, W. (1995) Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am. J. Pathol. 146,317 -322.[Abstract]
Imperato, J.P., Paleologos, N.A., and Vick, N.A. (1990) Effects of treatment on long-term survivors with malignant astrocytomas. Ann. Neurol. 28,818 -822.[CrossRef][ISI][Medline]
Kelly, P.J., Daumas-Duport, C., Scheithauer, B.W., Kall, B.A., and Kispert, D.B. (1987) Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin. Proc. 62,450 -459.[ISI][Medline]
Kramm, C.M., Rainov, N.G., Sena-Esteves, M., Chase, M., Pechan, P.A., Chiocca, E.A., and Breakefield, X.O. (1996) Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors. Hum. Gene Ther. 7, 291-300.[ISI][Medline]
Kramm, C.M., Chase, M., Herrlinger, U., Jacobs, A., Pechan, P.A., Rainov, N.G., Sena-Esteves, M., Aghi, M., Barnett, F.H., Chiocca, E.A., and Breakefield, X.O. (1997) Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum. Gene Ther. 8,2057 -2068.[ISI][Medline]
Linington, C., Berger, T., Perry, L., Weerth, S., Hinze-Selch, D., Zhang, Y., Lu, HC, Lassmann, H., and Wekerle, H. (1993) T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur. J. Immunol. 23,1364 -1372.[ISI][Medline]
Mahaley, M.S., Jr., Brooks, W.H., Roszman, T.L., Bigner, D.D., Dudka, L., Richardson and S. (1977) Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. J. Neurosurg. 46,467 -476.[ISI][Medline]
Mahaley, M.S., Jr., Bigner, D.D., Dudka, L.F., Wilds, P.R., Williams, D.H., Bouldin, TW, Whitaker, J.N., and Bynum, J.M. (1983a) Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic human glioma cells: a pilot study. J. Neurosurg. 59,201 -207.[CrossRef][ISI][Medline]
Mahaley, M.S., Jr., Gillespie, G.Y., Gillespie, R.P., Watkins, P.J., Bigner, D.D., Wikstrand, C.J., MacQueen, J.M., and Sanfilippo, F. (1983b) Immunobiology of primary intracranial tumors. Part 8: Serological responses to active immunization of patients with anaplastic gliomas. J. Neurosurg. 59,208 -216.[CrossRef][ISI][Medline]
Martuza, R.L., Malick, A., Markert, J.M., Ruffner, K.L., and Coen,
D.M. (1991) Experimental therapy of human glioma by means of a
genetically engineered virus mutant. Science
252,854
-856.
McKay, R. (1997) Stem cells in the central nervous
system. Science 276,66
-71.
Menzies, C.B., Gunar, M., Thomas, D.G., and Behan, P.O. (1980) Impaired thymus-derived lymphocyte function in patients with malignant brain tumour. Clin. Neurol. Neurosurg. 82,157 -168.[CrossRef][ISI][Medline]
Miescher, S., Whiteside, T.L., Carrel, S., and von Fliedner, V. (1986) Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J. Immunol. 136,1899 -1907.[Abstract]
Morford, L.A., Elliott, L.H., Carlson, S.L., Brooks, W.H., and Roszman, T.L. (1997) T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J. Immunol. 159,4415 -4425.[Abstract]
Moscatello, D.K., Holgado-Madruga, M., Godwin, A.K., Ramirez, G.,
Gunn, G., Zoltick, P.W., Biegel, J.A., Hayes, R.L., and Wong, A.J.
(1995) Frequent expression of a mutant epidermal growth factor
receptor in multiple human tumors. Cancer Res.
55,5536
-5539.
Nagane, M., Coufal, F., Lin, H., Bogler, O., Cavenee, W.K., Huang
and H.J. (1996) A common mutant epidermal growth factor receptor
confers enhanced tumorigenicity on human glioblastoma cells by increasing
proliferation and reducing apoptosis. Cancer Res.
56,5079
-5086.
Nishikawa, R., Ji, X.D., Harmon, R.C., Lazar, C.S., Gill, G.N.,
Cavenee, W.K., Huang and H.J. (1994) A mutant epidermal growth
factor receptor common in human glioma confers enhanced tumorigenicity.
Proc. Natl. Acad. Sci. U. S. A.
91,7727
-7731.
Pasteur, L. (1885) Methode pour prevenir la rage apres morsure. Comptes rendus de l'academie dessciences (Paris) 101,765 -774.
Remlinger, P. (1904) Contribution a l'etude de la toxine rabique (faits experimentaux et clinique). Compt. rend. Soc. de Biol. 56,346 -350.
Remlinger, P. (1905) Accidents paralytiques au cours du traitement antirabique. Ann. Inst. Pasteur 19,625 -646.
Reyes-Mugica, M., Rieger-Christ, K., Ohgaki, H., Ekstrand, B.C.,
Helie, M., Kleinman, G., Yahanda, A., Fearon, E.R., Kleihues, P., and Reale,
M.A. (1997) Loss of DCC expression and glioma progression.
Cancer Res. 57,382
-386.
Romine, J.S., and Salk, J. (1983) A study of myelin basic protein as a therapeutic probe in patients with multiple sclerosis. In: Hallpike, J.F., Adams, C.W.M., and Toutellotte, W.W. (Eds.), Multiple Sclerosis: pathology, diagnosis, and management. Baltimore: Williams & Wilkins. pp.621 -630.
Roszman, T.L., and Brooks, W.H. (1980) Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. Clin. Exp. Immunol. 39,395 -402.[ISI][Medline]
Roszman, T.L., Brooks, W.H., and Elliott, L.H. (1982) Immunobiology of primary intracranial tumors. VI. Suppressor cell function and lectin-binding lymphocyte subpopulations in patients with cerebral tumors. Cancer 50,1273 -1279.[CrossRef][ISI][Medline]
Roszman, T.L., Elliott, L.H., and Brooks, W.H. (1992) Proliferative potential of T-cell lymphocytes from gliomas. J. Neurosurg. 77,820 -821.[ISI][Medline]
Saas, P., Walker, P.R., Hahne, M., Quiquerez, A.L., Schnuriger, V., Perrin, G., French, L., Van Meir, E.G., de Tribolet, N., Tschopp, J., and Dietrich, P.Y. (1997) Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Invest. 99,1173 -1178.[ISI][Medline]
Sampson, J., Bigner, D., and Dranoff, G. (1998) Cytokine-based gene therapy for brain tumors. In: Chiocca, E.A., and Breakefield, X.O. (Eds.), Gene Therapy for Neurological Disorders and Brain Tumors. Totowa, New Jersey: Humana Press, pp.231 -294.
Sampson, J.H., Archer, G.E., Ashley, D.M., Fuchs, H.E., Hale, L.P.,
Dranoff, G., and Bigner, D.D. (1996) Subcutaneous vaccination
with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated
immunity against tumors located in the "immunologically
privileged" central nervous system. Proc. Natl. Acad. Sci. U.
S. A. 93,10399
-10404.
Sampson, J.H., Ashley, D.M., Archer, G.E., Fuchs, H.E., Dranoff, G., Hale, L.P., and Bigner, D.D. (1997) Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurgery 41,1365 -1373.[CrossRef][ISI][Medline]
Serano, R.D., Pegram, C.N., and Bigner, D.D. (1980) Tumorigenic cell culture lines from a spontaneous VM/Dk murine astrocytoma (SMA). Acta. Neuropathol.(Berl.) 51, 53-64.
Sobol, R.E., Fakhrai, H., Shawler, D., Gjerset, R., Dorigo, O., Carson, C., Khaleghi, T., Koziol, J., Shiftan, T.A., and Royston, I. (1995) Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther. 2,164 -167.[ISI][Medline]
Somasundaram, R., Zaloudik, J., Jacob, L., Benden, A., Sperlagh, M., Hart, E., Marks, G., Kane, M., Mastrangelo, M., and Herlyn, D. (1995) Induction of antigen-specific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody. J. Immunol. 155,3253 -3261.[Abstract]
Stuart, G., and Krikorian, K. (1930) A fatal neuro-paralytic accident of antirabies treatment. Lancet 1,1123 -1125.
Thomas, D.G., Lannigan, C.B., and Behan, P.O. (1975) Impaired cell-mediated immunity in human brain tumours. Lancet 1,1389 -1390. (Letter)[CrossRef][ISI][Medline]
Thompson, R.C., Pardoll, D.M., Jaffee, E.M., Ewend, M.G., Thomas, M.C., Tyler, B.M., and Brem, H. (1996) Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. J. Immunother. Emphasis. Tumor Immunol. 19,405 -413.[Medline]
Toda, M., Martuza, R.L., Kojima, H., and Rabkin, S.D.
(1998) In situ cancer vaccination: an IL-12 defective
vector/replication-competent herpes simplex virus combination induces local
and systemic antitumor activity. J. Immunol.
160,4457
-4464.
Tohma, Y., Gratas, C., Van Meir, E.G., Desbaillets, I., Tenan, M., Tachibana, O., Kleihues, P., and Ohgaki, H. (1998) Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. J. Neuropathol. Exp. Neurol. 57,239 -245.[ISI][Medline]
Trouillas, P. (1973) Immunology and immunotherapy of cerebral tumors. Current status. Rev. Neurol. (Paris) 128, 23-38.
Tuohy, V.K., Lu, Z.J., Sobel, R.A., Laursen, R.A., and Lees, M.B. (1988) A synthetic peptide from myelin proteolipid protein induces experimental allergic encephalomyelitis. J. Immunol. 141,1126 -1130.[Abstract]
Wakimoto, H., Abe, J., Tsunoda, R., Aoyagi, M., Hirakawa, K., and
Hamada, H. (1996) Intensified antitumor immunity by a cancer
vaccine that produces granulocyte-macrophage colony-stimulating factor plus
interleukin. Cancer Res.
56,1828
-1833.
Waksman, B.H., Porter, H., Lees, M.D., Adams, R.D., and Folch, J.
(1954) A study of the chemical nature of components of bovine
white matter effective in producing allergic encephalomyelitis in the rabbit.
J. Exp. Med. 100,451
-471.
Watanabe, K., Tachibana, O., Sata, K., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 6, 217-224.[ISI][Medline]
Wei, M.X., Tamiya, T., Chase, M., Boviatsis, E.J., Chang, T.K., Kowall, N.W., Hochberg, FH, Waxman, D.J., Breakefield, X.O., and Chiocca, E.A. (1994) Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum. Gene Ther. 5,969 -978.[ISI][Medline]
Wei, M.X., Tamiya, T., Hurford, R.K., Jr., Boviatsis, E.J., Tepper, R.I., and Chiocca, E.A. (1995) Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer. Hum. Gene Ther. 6, 437-443.[ISI][Medline]
Wekerle, H., Kojima, K., Lannes-Vieira, J., Lassmann, H., and Linington, C. (1994) Animal models. Ann. Neurol. 36 (Suppl.),S47 -53.
Wikstrand, C.J., Hale, L.P., Batra, S.K., Hill, M.L., Humphrey,
P.A., Kurpad, S.N., McLendon, R.E., Moscatello, D., Pegram, C.N., Reist, C.J.,
Traweek, S.T., Wong, A.J., Zalutsky, M.R., and Bigner, D.D.
(1995) Monoclonal antibodies against EGFRvIII are tumor specific
and react with breast and lung carcinomas and malignant gliomas.
Cancer Res. 55,3140
-3148.
Wong, A.J., Ruppert, J.M., Bigner, S.H., Grzeschik, C.H., Humphrey,
P.A., Bigner, D.D., and Vogelstein, B. (1992) Structural
alterations of the epidermal growth factor receptor gene in human gliomas.
Proc. Natl. Acad. Sci. U. S. A.
89,2965
-2969.
Wrann, M., Bodmer, S., de Martin, R., Siepl, C., Hofer-Warbinek, R., Frei, K., Hofer, E., and Fontana, A. (1987) T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO J. 6,1633 -1636.[ISI][Medline]
Young, H.F., Sakalas, R., and Kaplan, A.M. (1976) Inhibition of cell-mediated immunity in patients with brain tumors. Surg. Neurol. 5,19 -23.[Medline]
Yu, J.S., Wei, M.X., Chiocca, E.A., Martuza, R.L., and Tepper, R.I.
(1993) Treatment of glioma by engineered interleukin 4-secreting
cells. Cancer Res. 53,3125
-3128.
Yu, J.S., Burwick, J.A., Dranoff, G., and Breakefield, X.O. (1997) Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum. Gene Ther. 8,1065 -1072.[ISI][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
